These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Search MEDLINE/PubMed

  • Title: [Efficacy and safety of rituximab therapy for refractory/relapsing thrombotic thrombocytopenic purpura].
    Author: Cui J, Zhu TN, Zou N, Chen M, Zhao YQ.
    Journal: Zhongguo Yi Xue Ke Xue Yuan Xue Bao; 2013 Feb; 35(1):116-20. PubMed ID: 23469801.
    Abstract:
    OBJECTIVE: To evaluate the efficacy and safety of rituximab in treating patients with refractory and/or relapsing thrombotic thrombocytopenic purpura (TTP). METHODS: Totally three patients received rituximab as salvage therapy in our hospital. Rituximab was administered at a weekly dose of 375 mg/m(2) for 2 or 4 consecutive weeks. After clinical remission, patients were followed up every 3 months. RESULTS: All three patients achieved complete remission. The median time to platelet count recovery was 7 days (4-12 days) after the first rituximab infusion. During the follow-up (median: 12 months; range: 9-18 months), no patients experienced relapse. No side effect was noted during treatment and follow-up period. CONCLUSION: Therapy with rituximab is effective and well tolerated for patients with refractory or relapsing TTP.
    [Abstract] [Full Text] [Related] [New Search]